Everolimus in Anaplastic Thyroid Cancer: A Case Series
Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol.Methods: Patients with confirmed...
Main Authors: | Ethan J. Harris, Glenn J. Hanna, Nicole Chau, Guilherme Rabinowits, Robert Haddad, Danielle N. Margalit, Jonathan Schoenfeld, Roy B. Tishler, Justine A. Barletta, Matthew Nehs, Pasi Janne, Julian Huang, Phillip Groden, Alec Kacew, Jochen Lorch |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00106/full |
Similar Items
-
Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01) -
Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
by: Overwater IE, et al.
Published: (2019-07-01) -
Cyclic AMP-dependent signal transduction leading to mitogenesis in thyroid. Implication of the mammalian target of rapamycin (mTOR).
by: Blancquaert, Sara
Published: (2010) -
mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01) -
mTOR Pathways in Cancer and Autophagy
by: Mathieu Paquette, et al.
Published: (2018-01-01)